|
 The drug Breztri Aerosphere is being approved as a maintenance
treatment for patients with chronic obstructive pulmonary disease (COPD),
the third leading cause of death globally, AstraZeneca said.
Known as "smoker's lung", COPD is a progressively worsening and
potentially deadly condition that affects more than 380 million
people worldwide, primarily caused by smoking, but also by
occupational hazards such as air pollution or chemical fumes.
The approval for AstraZeneca comes at a time when the British
drugmaker is seeking to catch up with the runaway success of rival
Glaxosmithkline's Trelegy Ellipta drug.
COPD-related sales of Trelegy Ellipta more than tripled to 518
million pounds last year. Trimbow by Italy's Chiesi is another
competitor in the European market.
Breztri Aerosphere, which is a three-drug inhaler, is already
approved in Japan and China for patients with COPD and is under
regulatory review in the European Union, AstraZeneca said.
[to top of second column] |
Last month, data from a late-stage trial showed that Breztri reduced the risk of
a recurrence in flare-ups, or exacerbations, by between 13% and 24% when
compared to standard two-drug inhalers, and cut the risk of death from all
causes by 46%.
"Preventing exacerbations is central to the management of COPD ... Breztri
Aerosphere has demonstrated significant benefits in reducing exacerbations,"
Weill Cornell, an investigator in a late-stage trial that tested the drug, said.
Sales of Astra's respiratory drugs rose 10% last year, while oncology drugs saw
a 44% surge in revenues.
(Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Shounak Dasgupta
and Catherine Evans)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
